updated 9/9/2010 1:15:38 PM ET 2010-09-09T17:15:38

SAN DIEGO, Sept. 9, 2010 (GLOBE NEWSWIRE) -- BioMedTracker, a product of Sagient Research Systems, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, Thought Leader Opinions (TLO). This service provides its subscribers with direct access to the latest expert opinions in the disease areas that they follow within the intuitive BioMedTracker drug information platform.  The service provides its subscribers with over 700 recent interviews from:

  • 300 medical/clinical Thought Leaders
  • 30 Practice Specialties
  • 90 Indications

These interviews provide in-depth analysis on the following issues which are crucial to understanding the competitive landscape within a given pharmaceutical market:

  1. Whether a late stage drug will be approved by the FDA and/or EMA.
  2. Whether that drug's approval will affect current prescription practice.
  3. What market implications the recent results of a key trial will have.
  4. What mechanisms of action and targets show promise for earlier stage drugs in a particular indication.
  5. How recent safety concerns will affect how a doctor prescribes a particular drug or class of drugs.
  6. How the pricing of a new medicine will impact its uptake in the market

"With increasing volatility surrounding FDA Advisory Panel decisions in recent months, understanding what experts think about drugs in development before they reach the advisory panel has never been more important," said Robert Kyle, CEO of Sagient Research. "We launched the Thought Leader Opinion service to give our customers unparalleled access to this predictive information within the easy-to-use BioMedTracker drug database platform to help them better predict the approvability and future market potential of the drugs that they follow."

In conjunction with the launch of the Thought Leader Opinion Service, BioMedTracker is currently offering limited free trials.   Any biotech/pharmaceutical investor or industry professional who is interested in accessing this free trial may contact BioMedTracker by email at BioMedSubscribe@sagientresearch.com or call 858-200-2390. 

About MedPredict

The Thought Leader Opinion interviews in the BioMedTracker database are being provided through an exclusive partnership with MedPredict Market Research.

MedPredict has established long-standing, peer-to-peer relationships with medical researchers and thought leaders across many therapeutic categories. Their experienced analysts capitalize on these relationships to uncover deep insights into commercial and research activity, as well as near- and long-term category trends.

About BioMedTracker

BioMedTracker, a product of Sagient Research Systems, is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database.  Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

The Sagient Research Systems logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7294

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com